251 related articles for article (PubMed ID: 36073856)
21. Thyroid Follicular Cell-derived Carcinomas in a Background of Multiple Adenomatous Nodules Leading to a Diagnosis of
Liu A; Borges PM; Tay YS; Thompson LDR; Kong MX; Lai J
Anticancer Res; 2022 Mar; 42(3):1481-1485. PubMed ID: 35220242
[TBL] [Abstract][Full Text] [Related]
22. Novel dermatological and skeletal features associated with PTEN variant in PTEN hamartoma tumor syndrome.
Comeau D; Allain V; Maillet-Lebel N; Ben Amor M
Eur J Med Genet; 2023 Aug; 66(8):104798. PubMed ID: 37307869
[TBL] [Abstract][Full Text] [Related]
23. Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
Wang Q; Von T; Bronson R; Ruan M; Mu W; Huang A; Maira SM; Zhao JJ
Genes Dev; 2013 Jul; 27(14):1568-80. PubMed ID: 23873941
[TBL] [Abstract][Full Text] [Related]
24. [Cowden syndrome, or multiple hamartomatous tumor syndrome, in clinical endocrinology].
Sardinoux M; Raingeard I; Bessis D; Coupier I; Renard E; Bringer J
Ann Endocrinol (Paris); 2010 Sep; 71(4):264-73. PubMed ID: 20627233
[TBL] [Abstract][Full Text] [Related]
25. Small integral membrane protein 10 like 1 downregulation enhances differentiation of adipose progenitor cells.
Nebe M; Kehr S; Schmitz S; Breitfeld J; Lorenz J; Le Duc D; Stadler PF; Meiler J; Kiess W; Garten A; Kirstein AS
Biochem Biophys Res Commun; 2022 May; 604():57-62. PubMed ID: 35290761
[TBL] [Abstract][Full Text] [Related]
26. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome.
Nieuwenhuis MH; Kets CM; Murphy-Ryan M; Yntema HG; Evans DG; Colas C; Møller P; Hes FJ; Hodgson SV; Olderode-Berends MJ; Aretz S; Heinimann K; Gómez García EB; Douglas F; Spigelman A; Timshel S; Lindor NM; Vasen HF
Fam Cancer; 2014 Mar; 13(1):57-63. PubMed ID: 23934601
[TBL] [Abstract][Full Text] [Related]
27. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
Chen HH; Händel N; Ngeow J; Muller J; Hühn M; Yang HT; Heindl M; Berbers RM; Hegazy AN; Kionke J; Yehia L; Sack U; Bläser F; Rensing-Ehl A; Reifenberger J; Keith J; Travis S; Merkenschlager A; Kiess W; Wittekind C; Walker L; Ehl S; Aretz S; Dustin ML; Eng C; Powrie F; Uhlig HH
J Allergy Clin Immunol; 2017 Feb; 139(2):607-620.e15. PubMed ID: 27477328
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of TAS-117 in patients with advanced solid tumors harboring germline
Rodón J; Funchain P; Laetsch TW; Arkenau HT; Hervieu A; Singer CF; Murciano-Goroff YR; Chawla SP; Anthony K; Yamamiya I; Liu M; Halim AB; Benhadji KA; Takahashi O; Delaloge S
Future Oncol; 2022 Sep; 18(30):3377-3387. PubMed ID: 36039910
[TBL] [Abstract][Full Text] [Related]
29. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
30. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.
Orloff MS; Eng C
Oncogene; 2008 Sep; 27(41):5387-97. PubMed ID: 18794875
[TBL] [Abstract][Full Text] [Related]
31. Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome".
Galatola M; Paparo L; Duraturo F; Turano M; Rossi GB; Izzo P; De Rosa M
BMC Med Genet; 2012 Apr; 13():28. PubMed ID: 22520842
[TBL] [Abstract][Full Text] [Related]
32. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?
Mester JL; Moore RA; Eng C
Oncologist; 2013; 18(10):1083-90. PubMed ID: 24037976
[TBL] [Abstract][Full Text] [Related]
33. Cowden syndrome.
Gustafson S; Zbuk KM; Scacheri C; Eng C
Semin Oncol; 2007 Oct; 34(5):428-34. PubMed ID: 17920899
[TBL] [Abstract][Full Text] [Related]
34. Increased prevalence of eosinophilic gastrointestinal disorders in pediatric PTEN hamartoma tumor syndromes.
Henderson CJ; Ngeow J; Collins MH; Martin LJ; Putnam PE; Abonia JP; Marsolo K; Eng C; Rothenberg ME
J Pediatr Gastroenterol Nutr; 2014 May; 58(5):553-60. PubMed ID: 24345843
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological inhibition of mTORC1 prevents over-activation of the primordial follicle pool in response to elevated PI3K signaling.
Adhikari D; Risal S; Liu K; Shen Y
PLoS One; 2013; 8(1):e53810. PubMed ID: 23326514
[TBL] [Abstract][Full Text] [Related]
36. Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity.
Laury AR; Bongiovanni M; Tille JC; Kozakewich H; Nosé V
Thyroid; 2011 Feb; 21(2):135-44. PubMed ID: 21190448
[TBL] [Abstract][Full Text] [Related]
37. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.
Banneau G; Guedj M; MacGrogan G; de Mascarel I; Velasco V; Schiappa R; Bonadona V; David A; Dugast C; Gilbert-Dussardier B; Ingster O; Vabres P; Caux F; de Reynies A; Iggo R; Sevenet N; Bonnet F; Longy M
Breast Cancer Res; 2010; 12(4):R63. PubMed ID: 20712882
[TBL] [Abstract][Full Text] [Related]
38. Germline PTEN mutations are associated with a skewed peripheral immune repertoire in humans and mice.
Jaini R; Loya MG; King AT; Thacker S; Sarn NB; Yu Q; Stark GR; Eng C
Hum Mol Genet; 2020 Aug; 29(14):2353-2364. PubMed ID: 32588888
[TBL] [Abstract][Full Text] [Related]
39. Clinical Implications for Germline PTEN Spectrum Disorders.
Ngeow J; Sesock K; Eng C
Endocrinol Metab Clin North Am; 2017 Jun; 46(2):503-517. PubMed ID: 28476234
[TBL] [Abstract][Full Text] [Related]
40. Head circumference in the clinical detection of PTEN hamartoma tumor syndrome in a clinic population at high-risk of breast cancer.
Shiovitz S; Everett J; Huang SC; Orloff MS; Eng C; Gruber SB
Breast Cancer Res Treat; 2010 Nov; 124(2):459-65. PubMed ID: 20349131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
